Cargando…
Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer
BACKGROUND: Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme with immunomodulatory properties that has emerged as a potential immunotherapeutic target in human cancer. However, the role, expression pattern, and relevance of IDO1 in esophageal cancer (EC) are poorly understood. Here, we utilize gene...
Autores principales: | Rosenberg, Ari J., Wainwright, Derek A., Rademaker, Alfred, Galvez, Carlos, Genet, Matthew, Zhai, Lijie, Lauing, Kristen L., Mulcahy, Mary F., Hayes, John P., Odell, David D., Horbinski, Craig, Komanduri, Srinadh, Tetreault, Marie-Pier, Kim, Kwang-Youn A., Villaflor, Victoria M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955099/ https://www.ncbi.nlm.nih.gov/pubmed/29805749 http://dx.doi.org/10.18632/oncotarget.25235 |
Ejemplares similares
-
Identification
and Characterization of a Novel Indoleamine
2,3-Dioxygenase 1 Protein Degrader for Glioblastoma
por: Bollu, Lakshmi R., et al.
Publicado: (2022) -
Indoleamine 2,3-dioxygenase expression and overall survival in patients diagnosed with breast cancer in Pakistan
por: Asghar, Kashif, et al.
Publicado: (2019) -
Localization of Indoleamine 2,3-Dioxygenase-1 and Indoleamine 2,3-Dioxygenase-2 at the Human Maternal-Fetal Interface
por: Kudo, Yoshiki, et al.
Publicado: (2020) -
Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy
por: Brochez, Lieve, et al.
Publicado: (2021) -
Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges
por: Peng, Xuerun, et al.
Publicado: (2022)